[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hartford HealthCare\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100622238","using-breathing-techniques-to-ease-anxiety-in-icu-patients-awaiting-heart-transplants-100622238",false,"NCT07381023","Using Breathing Techniques to Ease Anxiety in ICU Patients Awaiting Heart Transplants","Effectiveness of Heart Rate Variability in Reducing Anxiety in Pre-Heart Transplant Candidates in the ICU","Inclusion Criteria\n\n* any gender\n* any race\u002Fethnicity\n* ≥18 years old with no upper limit\n* currently inpatient in the cardiac ICU, awaiting heart transplant\n* elevated anxiety symptoms as evidenced by cut scores on the Depression, Anxiety and Stress Scale (DASS-21) and the Cardiac Anxiety Questionnaire (CAQ) (Lovibond \\& Lovibond, 1995; Eifert et al., 2000).\n* proficiency in speaking, reading and writing in English Participants in this study must be proficient in English due to the language limitations of the study administrator. The intervention includes a teaching component that requires verbal instruction, psychoeducation, and interactive engagement, all of which will be conducted exclusively in English. At this time, the study administrator is only proficient in English and is unable to reliably deliver the intervention or assess participant understanding in other languages. To ensure consistency, accuracy, and fidelity of the intervention, as well as to maintain ethical standards in informed consent and participant comprehension, only English-speaking individuals will be eligible to participate.\n* able\u002Fwilling to consent to participate Exclusion Criteria\n* \\\u003C18 years of age\n* active psychosis or delirium\n* current neurological problems (e.g., stroke) at time of enrollment that would interfere with the ability to complete the practice\n* on a ventilator at time of enrollment\n* pregnancy\n* unable or unwilling to consent to participate","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn whether a breathing-based relaxation technique called heart rate variability biofeedback (HRVB) can help reduce anxiety in adult patients who are in the intensive care unit (ICU) and waiting for a heart transplant. The main questions it aims to answer are:\n\nCan HRVB reduce anxiety in patients awaiting heart transplantation in the ICU? Does HRVB help patients feel more in control of their emotions during this stressful time?\n\nParticipants will:\n\nComplete a brief anxiety assessment before and after the intervention Participate in a guided HRVB session using a breathing device or app Learn how to use the technique on their own for future stress management",[26,27],"Anxiety","Heart Transplant Patients",[29,30,26,31,32,33,34],"Heart Transplant Candidates","Heart Rate Variability Biofeedback","Breathing techniques","Behavioral Health in Transplant","Cardiac Anxiety","Biofeedback Therapy","NOT_YET_RECRUITING","2026-03-24",{"date":38,"type":39},"2026-03-27","ACTUAL",{"date":41,"type":20},"2026-03",{"date":43,"type":20},"2027-12",{"name":45,"class":46},"Hartford HealthCare","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":70,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100606457","pelvic-floor-disorder-symptoms-in-women-seeking-weight-loss-therapy-100606457","NCT07175805","Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy","Inclusion Criteria:\n\n* female\n* 18-89 years old\n* any race\u002Fethnicity\n* BMI ≥30 kg\u002Fm2\n* current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \\& Bariatric Surgery\n* able\u002Fwilling to give informed consent\n* have a home scale to measure weight\n\nPatients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm:\n\n* prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1\u002Fgastric inhibitory peptide (GIP1)\n* taking other weight loss agents (such as metformin)\n\nPatients meeting all the following criteria will be eligible to participate in the bariatric surgery arm:\n\n* plan to undergo gastric sleeve or gastric bypass surgery\n* taking weight loss agents which are not GLP-1 RA or GLP-1\u002FGIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1\u002FGIP1 medications after surgery.\n\nExclusion Criteria:\n\n* Pregnant\n* ≥90 years old\n* \\\u003C18 years old\n* BMI \\\u003C30 kg\u002Fm2\n* A history of bariatric surgery prior to enrollment\n* No home scale to measure weight\n* Active cancer",true,"FEMALE","90 Years",{"count":57,"type":20},200,"OBSERVATIONAL","The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understanding how different types of weight loss treatment impact pelvic floor symptoms will help clinicians guide which weight loss treatments are recommended for patients with pelvic floor symptoms in the future.",[61,62,63,64,65,66,67,68,69],"Lower Urinary Tract Symptoms","Stress Urinary Incontinence","Urge Urinary Incontinence","Overactive Bladder","Pelvic Organ Prolapse","Weight Loss","Fecal Incontinence","Bariatric Surgery","glp1 Agonist",[71,72,73,74,75,76,77,78,79],"lower urinary tract symtpoms","stress urinary incontinence","urge urinary incontinence","overactive bladder","pelvic organ prolapse","weight loss","fecal incontinence","bariatric surgery","glp1 agonist","2025-09-15",{"date":82,"type":39},"2025-09-16",{"date":84,"type":20},"2025-10",{"date":86,"type":20},"2027-06",{"name":45,"class":46},1,""]